Mail

Australia markets open in 6 hours 15 minutes

ALL ORDS
7,223.10
+30.30(+0.42%)
AUD/USD
0.6660
+0.0053(+0.81%)
ASX 200
7,015.20
+27.60(+0.39%)
OIL
76.81
+1.95(+2.60%)
GOLD
2,036.30
+23.90(+1.19%)
Bitcoin AUD
56,811.15
+1,297.38(+2.34%)

FEELING THE PINCH?

Beat the cost-of-living squeeze with our pro tips and helpful hacks - sign up now

Corcept Therapeutics Incorporated (CORT)

NasdaqCM - NasdaqCM Real-time price. Currency in USD

Add to watchlist

25.21

-0.06

(-0.24%)

As of 11:45AM EST. Market open.

Currency in USD

Valuation measures⁴

Market cap (intra-day)	2.60B
Enterprise value	2.25B
Trailing P/E	31.59
Forward P/E	26.18
PEG ratio (5-yr expected)	N/A
Price/sales (ttm)	6.35
Price/book (mrq)	5.64
Enterprise value/revenue	5.00
Enterprise value/EBITDA	22.37

Trading information

Stock price history

Beta (5Y monthly)	0.43
52-week change ³	-1.13%
S&P500 52-week change ³	14.98%
52-week high ³	34.28
52-week low ³	17.86
50-day moving average ³	27.61
200-day moving average ³	25.30

Share statistics

Avg vol (3-month) ³	750.9k
Avg vol (10-day) ³	566.93k
Shares outstanding ⁵	103.08M
Implied shares outstanding ⁶	103.08M
Float ⁸	84.65M
% held by insiders ¹	11.61%
% held by institutions ¹	86.56%
Shares short (14 Nov 2023) ⁴	15.27M
Short ratio (14 Nov 2023) ⁴	19.18
Short % of float (14 Nov 2023) ⁴	23.87%
Short % of shares outstanding (14 Nov 2023) ⁴	14.81%
Shares short (prior month 12 Oct 2023) ⁴	14.96M

Dividends & splits

Forward annual dividend rate ⁴	N/A
Forward annual dividend yield ⁴	N/A
Trailing annual dividend rate ³	0.00
Trailing annual dividend yield ³	0.00%
5-year average dividend yield ⁴	N/A
Payout ratio ⁴	0.00%
Dividend date ³	N/A
Ex-dividend date ⁴	N/A
Last split factor ²	N/A
Last split date ³	N/A

Financial highlights

Fiscal year

Fiscal year ends	30 Dec 2022
Most-recent quarter (mrq)	29 Sept 2023

Profitability

Profit margin	20.31%
Operating margin (ttm)	25.22%

Management effectiveness

Return on assets (ttm)	10.88%
Return on equity (ttm)	19.55%

Income statement

Revenue (ttm)	450.03M
Revenue per share (ttm)	4.29
Quarterly revenue growth (yoy)	21.50%
Gross profit (ttm)	396.47M
EBITDA	98.77M
Net income avi to common (ttm)	90.89M
Diluted EPS (ttm)	0.80
Quarterly earnings growth (yoy)	-9.30%

Balance sheet

Total cash (mrq)	355.22M
Total cash per share (mrq)	3.45
Total debt (mrq)	225k
Total debt/equity (mrq)	0.05%
Current ratio (mrq)	3.54
Book value per share (mrq)	4.48

Cash flow statement

Operating cash flow (ttm)	154.54M
Levered free cash flow (ttm)	160.15M